Clinical Trial Update: Effects of an Oxymizer® During Daytime in Patients With Pulmonary Fibrosis (IPF) [NA]

View source ↗

Summary

A completed clinical trial update examines the daytime use of the Oxymizer oxygen-conserving device in patients with idiopathic pulmonary fibrosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis

Drugs mentioned

• Oxymizer

Snippet

Sponsor: Schön Klinik Berchtesgadener Land | Conditions: Idiopathic Pulmonary Fibrosis | NA | Status: COMPLETED